Navigation Links
BioMS Medical announces its intention to renew a normal course issuer bid
Date:8/20/2007

Toronto Stock Exchange Symbol: MS

EDMONTON, Aug. 20 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS) a leading developer in the treatment of multiple sclerosis (MS), announced today that it is renewing its normal course issuer bid. Under the bid, which will be conducted pursuant to the rules of the Toronto Stock Exchange ("TSX"), the Company may purchase up to 1,000,000 of its Class A common shares (the "Common Shares") representing approximately 1.09% of the Company's issued and outstanding Common Shares.

The bid will commence August 24, 2007 and will expire August 23, 2008 or such earlier date as the Company may complete its purchases. The price at which the Company will purchase its shares will be the market price thereof at the time of acquisition. Purchases of Common Shares will be made in the open market through the facilities of the TSX. Any Common Shares acquired by the Company will be cancelled. The Company has 91,356,923 Common Shares issued and outstanding as of August 17, 2007. During the previous 12 months, the Company acquired 16,100 of its Common Shares at an average price of $2.68 per share by way of a normal course issuer bid. The average daily trading volume of the Common Shares on the TSX (exclusive of purchases under the Company's previous normal course issuer bid) for the period February 1, 2007 to July 31, 2007 was 62,244 shares.

The Board of Directors of the Company believes that the market price of the Common Shares may not fully reflect the value of the Company's business and its future business prospects. As a result, the Board has concluded that the purchase and cancellation of the Common Shares may represent an appropriate and desirable use of the Company's funds and provide market stability.

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.

Copyright©2007 PR Newswire.

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Barriers will not stop convergence of medical technologies
3. Medical College team creates website for tracking flu
4. Biomedical engineering conference invites manufacturers
5. Visions: Wade offers straight talk on e-medical records
6. Merge unveils updated medical imaging software
7. Medical College receives $1.4M cancer grant
8. Medical technology firm lands $100K federal grant
9. Doyle outlines spending for Medical College, UWM
10. And the winners in medical design are
11. Manufacturing partnership will move into biotech and biomedical spaces
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Executive search firm, Slone ... Analytical Services. Harvill is a distinguished life sciences expert with a proven track ... leader in a wide range of services related to laboratory testing and analysis ...
(Date:3/27/2017)... Infectex Ltd., a Russian portfolio company of Maxwell Biotech Venture ... added to the standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). ... USA ) and the US National Institutes of Health. ... ... Logo ...
(Date:3/27/2017)... ... March 27, 2017 , ... A research team ... vascular grafts in JoVE’s Video Journal, the world’s first peer-reviewed scientific video journal. ... of treating coronary artery disease (CAD). Lam is an assistant professor at the ...
(Date:3/24/2017)... and ROCKVILLE, Md. , March ... of Maxwell Biotech Venture Fund (MBVF), today announced positive ... added to the standard drug therapy regimen in patients ... small molecule drug discovered by scientists at Sequella, Inc. ... Institutes of Health. A total of ...
Breaking Biology Technology:
(Date:3/6/2017)... SAN MATEO, Calif. , March 6, 2017 ... predictive marketing and sales technology, today announced Predictive ... (AI) solution for infusing actionable sales intelligence into ... customers to automatically enable their sales organizations with ... contextual messages that allow for intelligent engagement. Predictive ...
(Date:3/2/2017)... 2017 Summary This report provides ... KGaA and its partnering interests and activities since 2010. ... Description The Partnering Deals and Alliance since 2010 report ... one of the world,s leading life sciences companies. ... to ensure inclusion of the most up to date ...
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
Breaking Biology News(10 mins):